RecruitingPhase 3Drug trialCanakinumab for the Treatment of Postprandial HypoglycemiaThe primary objective of this randomized trial is to test whether a treatment with canakinumab is superior to placebo in patients with postprandial hypoglycemia after bariatric surgery, that is if it improves health related quality of life (mentally or physically) or reduces the risk of hypoglycemic events.